vs

Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

AMES NATIONAL CORP is the larger business by last-quarter revenue ($18.7M vs $11.0M, roughly 1.7× C4 Therapeutics, Inc.). AMES NATIONAL CORP runs the higher net margin — 34.9% vs -186.0%, a 220.8% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 26.7%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 19.5%).

Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

ATLO vs CCCC — Head-to-Head

Bigger by revenue
ATLO
ATLO
1.7× larger
ATLO
$18.7M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+86.1% gap
CCCC
112.8%
26.7%
ATLO
Higher net margin
ATLO
ATLO
220.8% more per $
ATLO
34.9%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
19.5%
ATLO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATLO
ATLO
CCCC
CCCC
Revenue
$18.7M
$11.0M
Net Profit
$6.5M
$-20.5M
Gross Margin
Operating Margin
44.3%
-210.1%
Net Margin
34.9%
-186.0%
Revenue YoY
26.7%
112.8%
Net Profit YoY
85.4%
40.7%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLO
ATLO
CCCC
CCCC
Q4 25
$18.7M
$11.0M
Q3 25
$16.6M
$11.2M
Q2 25
$16.1M
$6.5M
Q1 25
$15.5M
$7.2M
Q4 24
$14.7M
$5.2M
Q3 24
$13.5M
$15.4M
Q2 24
$13.5M
$12.0M
Q1 24
$13.1M
$3.0M
Net Profit
ATLO
ATLO
CCCC
CCCC
Q4 25
$6.5M
$-20.5M
Q3 25
$4.6M
$-32.2M
Q2 25
$4.5M
$-26.0M
Q1 25
$3.4M
$-26.3M
Q4 24
$3.5M
$-34.6M
Q3 24
$2.2M
$-24.7M
Q2 24
$2.2M
$-17.7M
Q1 24
$2.3M
$-28.4M
Operating Margin
ATLO
ATLO
CCCC
CCCC
Q4 25
44.3%
-210.1%
Q3 25
34.5%
-306.4%
Q2 25
35.0%
-441.0%
Q1 25
27.4%
-402.9%
Q4 24
29.4%
-728.4%
Q3 24
19.4%
-183.9%
Q2 24
19.0%
-178.6%
Q1 24
20.8%
-1060.2%
Net Margin
ATLO
ATLO
CCCC
CCCC
Q4 25
34.9%
-186.0%
Q3 25
27.5%
-286.4%
Q2 25
28.0%
-402.6%
Q1 25
22.3%
-363.7%
Q4 24
23.8%
-667.8%
Q3 24
16.4%
-160.6%
Q2 24
16.2%
-147.6%
Q1 24
17.6%
-933.2%
EPS (diluted)
ATLO
ATLO
CCCC
CCCC
Q4 25
$-0.09
Q3 25
$-0.44
Q2 25
$-0.37
Q1 25
$-0.37
Q4 24
$-0.50
Q3 24
$-0.35
Q2 24
$-0.26
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLO
ATLO
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$126.8M
$74.6M
Total DebtLower is stronger
$18.4M
Stockholders' EquityBook value
$207.9M
$256.6M
Total Assets
$2.1B
$359.1M
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLO
ATLO
CCCC
CCCC
Q4 25
$126.8M
$74.6M
Q3 25
$108.2M
$58.8M
Q2 25
$95.2M
$78.2M
Q1 25
$163.4M
$51.3M
Q4 24
$101.2M
$55.5M
Q3 24
$59.0M
$59.6M
Q2 24
$63.4M
$73.1M
Q1 24
$111.4M
$89.7M
Total Debt
ATLO
ATLO
CCCC
CCCC
Q4 25
$18.4M
Q3 25
Q2 25
Q1 25
Q4 24
$20.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ATLO
ATLO
CCCC
CCCC
Q4 25
$207.9M
$256.6M
Q3 25
$200.6M
$154.4M
Q2 25
$193.0M
$174.1M
Q1 25
$183.1M
$195.1M
Q4 24
$174.7M
$216.0M
Q3 24
$183.4M
$242.7M
Q2 24
$167.1M
$247.1M
Q1 24
$165.5M
$258.3M
Total Assets
ATLO
ATLO
CCCC
CCCC
Q4 25
$2.1B
$359.1M
Q3 25
$2.1B
$265.5M
Q2 25
$2.1B
$296.5M
Q1 25
$2.2B
$319.5M
Q4 24
$2.1B
$349.6M
Q3 24
$2.1B
$376.1M
Q2 24
$2.1B
$381.1M
Q1 24
$2.2B
$398.4M
Debt / Equity
ATLO
ATLO
CCCC
CCCC
Q4 25
0.09×
Q3 25
Q2 25
Q1 25
Q4 24
0.11×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLO
ATLO
CCCC
CCCC
Operating Cash FlowLast quarter
$21.3M
$-22.1M
Free Cash FlowOCF − Capex
$20.7M
FCF MarginFCF / Revenue
110.8%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$34.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLO
ATLO
CCCC
CCCC
Q4 25
$21.3M
$-22.1M
Q3 25
$2.8M
$-31.2M
Q2 25
$4.0M
$-12.1M
Q1 25
$7.1M
$-33.3M
Q4 24
$14.3M
$-17.9M
Q3 24
$3.1M
$-24.1M
Q2 24
$3.9M
$-5.0M
Q1 24
$1.4M
$-18.1M
Free Cash Flow
ATLO
ATLO
CCCC
CCCC
Q4 25
$20.7M
Q3 25
$2.6M
$-31.6M
Q2 25
$3.9M
Q1 25
$6.9M
Q4 24
$14.0M
$-17.9M
Q3 24
$3.0M
$-24.1M
Q2 24
$3.8M
$-5.2M
Q1 24
$1.3M
FCF Margin
ATLO
ATLO
CCCC
CCCC
Q4 25
110.8%
Q3 25
16.0%
-281.5%
Q2 25
24.2%
Q1 25
44.8%
Q4 24
94.9%
-346.5%
Q3 24
22.5%
-157.2%
Q2 24
28.1%
-43.1%
Q1 24
10.0%
Capex Intensity
ATLO
ATLO
CCCC
CCCC
Q4 25
3.4%
Q3 25
0.6%
3.7%
Q2 25
0.7%
Q1 25
1.3%
Q4 24
2.0%
0.1%
Q3 24
0.5%
0.1%
Q2 24
0.7%
1.6%
Q1 24
0.5%
0.0%
Cash Conversion
ATLO
ATLO
CCCC
CCCC
Q4 25
3.28×
Q3 25
0.60×
Q2 25
0.89×
Q1 25
2.07×
Q4 24
4.07×
Q3 24
1.40×
Q2 24
1.78×
Q1 24
0.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons